Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

Abstract

Background

How patients experience the symptoms/signs of psoriasis is highly relevant for assessing treatment response.

Objectives

Compare outcomes with guselkumab, placebo, and adalimumab utilizing the novel, validated Psoriasis Symptoms and Signs Diary (PSSD).

Methods

VOYAGE 1 is an on-going, phase III, double-blinded, controlled trial of patients with moderate-to-severe psoriasis. Patients were randomized to guselkumab 100 mg every-8-weeks; placebo-to-guselkumab 100 mg every-8-weeks; or adalimumab 40 mg every-2-weeks. The PSSD was self-administered to assess symptoms (i.e., itch, skin tightness, burning, stinging, pain) and signs (i.e., dryness, cracking, scaling, shedding/flaking, redness, bleeding) of psoriasis (0-10 [absent-to-worst-imaginable]) every 24-hours. Symptom and sign summary scores were derived (0-100) based on average scores of the individual symptoms and signs. Proportions of patients with clinically meaningful improvements and symptom- and sign-free scores of 0 were evaluated across treatment groups at weeks 16, 24, and 48.

Results

At baseline, 652/837 randomized patients had PSSD scores. The proportion of patients achieving clinically meaningful improvements in PSSD summary scores was significantly higher in the guselkumab group compared with the placebo group at week 16 (p<0.001) and compared with the adalimumab group at weeks 24 (p=0.002) and 48 (p<0.001). The proportions of patients achieving PSSD symptom and sign summary scores of 0 (i.e., symptom- and sign-free) were significantly higher for guselkumab vs. placebo at week 16 and vs. adalimumab at weeks 24 and 48 (all p<0.001).

Conclusions

Based on PSSD scores, greater improvements in symptoms and signs of psoriasis were reported by patients treated with guselkumab compared with placebo at week 16 or adalimumab through 48 weeks.

This article is protected by copyright. All rights reserved.

http://ift.tt/2D7axAY